mProX™ Human GPR32 Stable Cell Line

Product Information

Target Protein

GPR32

Target Family

Orphan Family

Target Protein Species

Human

Host Cell Type

CHO-K1;HEK293

Target Classification

GPCR Cell Lines

Gene ID

Human: 2854

UniProt ID

Human: O75388

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

GPR32 has been identified as a receptor for resolvin D1, a molecule known to regulate the resolution of inflammation. This receptor's activation has been linked to atheroprotection, suggesting its potential role in cardiovascular health. Furthermore, studies have shown that GPR32 can modulate inflammatory responses, emphasizing its significance in conditions like sepsis and other inflammatory diseases. The receptor's ability to influence macrophage behavior further highlights its potential therapeutic implications.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human GPR32 Stable Cell Line (S01YF-0923-PY189). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Helen (Verified Customer)

What is the function of GPR32 in cellular signaling? Sep 13 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

GPR32, known as G protein-coupled receptor 32 or the RvD1 receptor, is a seven-transmembrane G protein-coupled orphan receptor. It specifically interacts with Resolvin D1 (RvD1) and Lipoxin A4, playing a role in resolving acute inflammation. The interactions of GPR32 with these ligands suggest its involvement in inflammatory resolution processes, which can be crucial for studying inflammatory diseases and developing potential therapeutic strategies. Sep 13 2022

chat Michelle (Verified Customer)

What are the potential applications of GPR32 custom cell line products in research? Mar 01 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

GPR32 custom cell line products can serve as invaluable tools in understanding the molecular mechanisms underlying inflammation resolution. They can be used to study the receptor's signaling pathways, ligand interactions, and its role in various inflammatory conditions. Additionally, these custom cell lines can facilitate drug discovery efforts aimed at identifying new anti-inflammatory agents or therapies that modulate GPR32 activity, which could be beneficial in treating a range of inflammatory diseases. Mar 01 2021

Published Data

Fig.1 The dose-response experiments were conducted using RvD1 and LXA4 on β-arrestin cells that stably expressed GPR32.

When GPR32-β-arrestin cells were exposed to RvD1, a concentration-dependent rise in β-arrestin and receptor interactions was observed, with an estimated EC50 of approximately 8.8 × 10^−12 M. Simultaneously, incubation with LXA4 resulted in a dose-dependent elevation in GPR32 activation (EC50 ∼3.4 × 10^−11 M), revealing that both RvD1 and LXA4 had a direct activating effect on GPR32. These results highlight the direct activation of GPR32 by both compounds.

Ref: Krishnamoorthy, Sriram, et al. "Resolvin D1 binds human phagocytes with evidence for proresolving receptors." Proceedings of the National Academy of Sciences 107.4 (2010): 1660-1665.

Pubmed: 20080636

DOI: 10.1073/pnas.0907342107

Research Highlights

Carranza-Martin AC, et al. "Effects of polyunsaturated fatty acid supplementation on plasma and follicular ." Journal of animal science, 2023.
The study aimed to evaluate the effects of n-3 PUFA supplementation on reproductive parameters in ewes. Participants were divided into three groups: a control group without fatty acid supplementation, a group with 0.5% n-3 PUFA supplementation, and a group with 1% n-3 PUFA supplementation. Participants' body weight, BCS, and blood samples were obtained at different time points. Ewes were also synchronized, superstimulated, and ovariectomized for further analysis. Results showed a positive correlation between plasma and follicular fluid RvD1 concentration, indicating a potential link between both compartments. Furthermore, supplementation with n-3 PUFA was found to decrease IL-1beta and increase GPX1 mRNA abundance, potentially having beneficial effects on follicle development.
Pubmed: 37721095 DOI: 10.1093/jas/skad310

Gao J, et al. "Lung Inflammation Resolution by RvD1 and RvD2 in a Receptor-Dependent Manner.." Pharmaceutics, 2023.
The resolution of inflammation is a process that actively involves specialized pro-resolving mediators (SPMs) to combat invading microbes and repair tissue damage. Two SPMs, RvD1 and RvD2, derived from DHA, have shown promise in treating inflammation disorders. However, the mechanisms of how they promote inflammation resolution in the lungs through their effects on vasculature and immune cells are not fully understood. This study aimed to investigate the interactions between RvD1 and RvD2 on endothelial cells and neutrophils in vitro and in vivo. In an acute lung inflammation (ALI) mouse model, RvD1 and RvD2 were found to resolve inflammation through their receptors (ALX/GPR32 or GPR18), and by enhancing macrophage phagocytosis of apoptotic neutrophils, which could be a potential molecular mechanism for inflammation resolution. Notably, RvD1 showed higher efficacy than RvD2, possibly due to distinct downstream signaling pathways. This research suggests that targeted delivery of these SPMs to inflammatory sites may serve as a novel approach for treating various inflammatory diseases.
Pubmed: 37242769 DOI: 10.3390/pharmaceutics15051527